Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Can a Joint Assessment Provide Relevant Information for National/Local Relative Effectiveness Assessments? An In-Depth Comparison of Pazopanib Assessments.

Kleijnen S, Fathallah M, van der Linden MW, Vancraeynest P, Dahmani B, Timoney A, De Boer A, Leufkens HG, Goettsch WG.

Value Health. 2015 Jul;18(5):663-72. doi: 10.1016/j.jval.2015.03.1790. Epub 2015 Jun 10.

2.

Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain.

Villa G, Hernández-Pastor LJ.

BMC Cancer. 2013 Sep 2;13:399. doi: 10.1186/1471-2407-13-399.

3.

Piloting international production of rapid relative effectiveness assessments of pharmaceuticals.

Kleijnen S, Pasternack I, Rannanheimo P, Vuola JM, Van de Casteele M, Bucsics A, Pulis IZ, Di Bidino R, Sacchini D, Montilla S, Abrishami P, Sammut SM, Muscolo LA, Happonen P, Goettsch WG.

Int J Technol Assess Health Care. 2014 Nov;30(5):521-9. doi: 10.1017/S0266462314000622.

PMID:
25747562
4.

Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States.

Delea TE, Amdahl J, Diaz J, Nakhaipour HR, Hackshaw MD.

J Manag Care Spec Pharm. 2015 Jan;21(1):46-54, 54a-b.

5.

Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence.

Nazha S, Tanguay S, Kapoor A, Jewett M, Kollmannsberger C, Wood L, Bjarnason GAG, Heng D, Soulières D, Reaume MN, Basappa N, Lévesque E, Dragomir A.

Clin Drug Investig. 2018 Dec;38(12):1155-1165. doi: 10.1007/s40261-018-0705-6.

PMID:
30267257
6.

Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal.

Kilonzo M, Hislop J, Elders A, Fraser C, Bissett D, McClinton S, Mowatt G, Vale L.

Pharmacoeconomics. 2013 Jan;31(1):15-24. doi: 10.1007/s40273-012-0006-5. Review.

PMID:
23329590
7.

Relative effectiveness assessment of pharmaceuticals: similarities and differences in 29 jurisdictions.

Kleijnen S, George E, Goulden S, d'Andon A, Vitré P, Osińska B, Rdzany R, Thirstrup S, Corbacho B, Nagy BZ, Leufkens HG, de Boer A, Goettsch WG.

Value Health. 2012 Sep-Oct;15(6):954-60. doi: 10.1016/j.jval.2012.04.010. Epub 2012 Jun 20.

8.

Health care costs among renal cancer patients using pazopanib and sunitinib.

Hansen RN, Hackshaw MD, Nagar SP, Arondekar B, Deen KC, Sullivan SD, Ramsey SD.

J Manag Care Spec Pharm. 2015 Jan;21(1):37-44, 44a-d.

9.
10.

[Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].

Brotelle T, Bay JO.

Bull Cancer. 2014 Jun;101(6):641-6. doi: 10.1684/bdc.2014.1981. Review. French.

PMID:
24977453
11.

Pazopanib for the treatment of metastatic renal cell carcinoma.

Pick AM, Nystrom KK.

Clin Ther. 2012 Mar;34(3):511-20. doi: 10.1016/j.clinthera.2012.01.014. Epub 2012 Feb 16. Review.

PMID:
22341567
12.

Health Care Costs Among Renal Cancer Patients Using Pazopanib and Sunitinib.

MacLean EA, Sandin R, Mardekian J.

J Manag Care Spec Pharm. 2015 Sep;21(9):841-3.

13.

Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries.

Kleijnen S, Lipska I, Leonardo Alves T, Meijboom K, Elsada A, Vervölgyi V, d'Andon A, Timoney A, Leufkens HG, De Boer A, Goettsch WG.

Ann Oncol. 2016 Sep;27(9):1768-75. doi: 10.1093/annonc/mdw233. Epub 2016 Jun 20.

PMID:
27329251
14.

Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover--The Case of Pazopanib in Advanced Renal Cell Carcinoma.

Diaz J, Sternberg CN, Mehmud F, Delea TE, Latimer N, Pandite L, Motzer RJ.

Oncology. 2016;90(3):119-26. doi: 10.1159/000443647. Epub 2016 Feb 23.

15.

Cost-Effectiveness of Pazopanib Versus Sunitinib for Renal Cancer in the United States.

Benedict A, Ramaswamy K, Sandin R.

J Manag Care Spec Pharm. 2015 Sep;21(9):834-40.

16.

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.

Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, Zarba JJ, Gladkov OA, Lee E, Szczylik C, McCann L, Rubin SD, Chen M, Davis ID.

Eur J Cancer. 2013 Apr;49(6):1287-96. doi: 10.1016/j.ejca.2012.12.010. Epub 2013 Jan 12.

PMID:
23321547
17.

The Authors Respond.

Delea TE, Amdahl J, Diaz J, Nakhaipour HR, El Khoury MH.

J Manag Care Spec Pharm. 2015 Sep;21(9):836-40. No abstract available.

PMID:
26536676
18.

[Atrial flutter probably related to pazopanib: A case report].

Puebla Villaescusa A, Díaz Gómez E, Salcedo Mingoarranz ÁL, Ramírez Cruz S, Hidalgo Correas FJ, García Díaz B.

Farm Hosp. 2018 Jan 1;42(1):33-34. doi: 10.7399/fh.10887. Spanish. No abstract available.

19.

Pazopanib for the treatment of renal cancer.

Al-Marrawi MY, Rini B.

Expert Opin Pharmacother. 2011 May;12(7):1171-89. doi: 10.1517/14656566.2011.571206. Epub 2011 Apr 7. Review. Erratum in: Expert Opin Pharmacother. 2011 Jun;12(8):1349.

PMID:
21470066
20.

Standardized reporting for rapid relative effectiveness assessments of pharmaceuticals.

Kleijnen S, Pasternack I, Van de Casteele M, Rossi B, Cangini A, Di Bidino R, Jelenc M, Abrishami P, Autti-Rämö I, Seyfried H, Wildbacher I, Goettsch WG.

Int J Technol Assess Health Care. 2014 Nov;30(5):488-96. doi: 10.1017/S0266462314000609.

PMID:
25747557

Supplemental Content

Support Center